1. Academic Validation
  2. Interferon Regulatory Factor-1 (IRF1) activates autophagy to promote liver ischemia/reperfusion injury by inhibiting β-catenin in mice

Interferon Regulatory Factor-1 (IRF1) activates autophagy to promote liver ischemia/reperfusion injury by inhibiting β-catenin in mice

  • PLoS One. 2020 Nov 2;15(11):e0239119. doi: 10.1371/journal.pone.0239119.
Bing Yan 1 2 Jing Luo 1 Christof Kaltenmeier 1 Qiang Du 1 Donna B Stolz 3 Patricia Loughran 3 Yihe Yan 1 Xiao Cui 1 David A Geller 1
Affiliations

Affiliations

  • 1 Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States of America.
  • 2 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, PR China.
  • 3 Center for Biologic Imaging, University of Pittsburgh Medical School, Pittsburgh, PA, United States of America.
Abstract

Autophagy is an important factor in liver ischemia-reperfusion injury. In the current study we investigate the function of interferon regulatory factor-1 (IRF1) in regulating Autophagy to promote hepatic ischemia reperfusion injury (IR). The high expression of IRF1 during hepatic IR exhibited increased liver damage and was associated with activation of Autophagy shown by Western blot markers, as well as immunofluorescent staining for autophagosomes. These effects were diminished by IRF1 deficiency in IRF1 knock out (KO) mice. Moreover, the Autophagy Inhibitor 3-MA decreased IR-induced liver necrosis and markedly abrogated the rise in liver injury tests (AST/ALT). β-catenin expression decreased during liver IR and was increased in the IRF1 KO mice. Immunoprecipitation assay showed the binding between IRF1 and β-catenin. Overexpression of IRF1 induced Autophagy and also inhibited the expression of β-catenin. β-catenin Inhibitor increased Autophagy while β-catenin agonist suppressed Autophagy in primary mouse hepatocytes. These results indicate that IRF1 induced Autophagy aggravates hepatic IR injury in part by inhibiting β-catenin and suggests that targeting IRF1 may be an effective strategy in reducing hepatic IR injury.

Figures
Products